Warning: session_start(): open(/opt/alt/php74/var/lib/php/session/sess_75889ea981d66309d05b9c87f94dd6db, O_RDWR) failed: Disk quota exceeded (122) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278

Warning: session_start(): Failed to read session data: files (path: /opt/alt/php74/var/lib/php/session) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278
Is Axim The Real Deal Or A Biotech Bottom Feeder? - Mushroomstocks | Mushroomstocks
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Is Axim The Real Deal Or A Biotech Bottom Feeder?

Aug 23, 2017 • 10:27 AM EDT
Canada Stocks (8).png
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Yesterday, Axim Biotechnologies (AXIM) released its second quarter financial and operating results for the period that ended on June 30th and the biotech firm provided an overview of its recent highlights.

Before we break into these results, we want to state that we are cautious with Axim and believe there are much better biotech opportunities available. If we were to take a look at the shares, we would have a short-term swing trade approach because Axim Biotech is not a long-term opportunity.

Not Buying into the Hype

Axim has frequently presented itself as one of the best cannabis biotech opportunities, however, this could not be further from the truth.

Earlier this year, AXIM was reported to have the broadest pipeline in the cannabis industry, which is a very misleading statement. The article stated, “AXIM Biotech has developed one of the industry’s most diverse clinical pipelines with nine clinical programs in development (several have been recently added).”

Axim Doesn’t Have the Resources to Accomplish its Goals

When investors think of the leading biotech company levered to the cannabis industry, the first name that comes to mind is GW Pharmaceutical (GWPH). The company has by far, the largest and most advanced pipeline of products in advanced stages of FDA testing. GW also has the capital to support the costs of clinical trials ($369.5 million in cash as of June 30th).

Axim on the other hand, does not have the capital it needs to fund its initiatives and clinical trials. The company admitted this in its earnings report and said that it does not have the resources to accomplish its objectives during the next twelve months. The financial report stated that these conditions raise substantial doubt about Axim’s ability to continue as a going concern.

The process of getting a drug through clinical trials, approved by the FDA, and onto the market is expensive…like tens of millions expensive. While these costs are substantial, the reward is worth it for the companies that are successful and these opportunities are attractive to investors.

When it comes to Axim though, investors clearly believe the risk is too significant or the company’s balance sheet would be flush with cash.

A Lower-Quality Volatile Biotech Opportunity

While we continue to view the biotech sector as one of the greatest beneficiaries of the legal cannabis movement, investors need to be selective if they want to be successful.

Axim has come well off its recent highs and the shares have fallen more than 50% from its May highs. AXIM is trending higher after falling below $5 last week and the shares are up more than 40% from these lows.

We are on the sidelines with this one…

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.

Fatal error: Uncaught ErrorException: md5_file(/home/useaicwl/public_html/wp-content/litespeed/css/16073ae2fc0514f93e51e58f070a7af1.css.tmp): failed to open stream: No such file or directory in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php:126 Stack trace: #0 [internal function]: litespeed_exception_handler(2, 'md5_file(/home/...', '/home/useaicwl/...', 126, Array) #1 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php(126): md5_file('/home/useaicwl/...') #2 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(797): LiteSpeed\Optimizer->serve('https://mushroo...', 'css', true, Array) #3 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(319): LiteSpeed\Optimize->_build_hash_url(Array) #4 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(252): LiteSpeed\Optimize->_optimize() #5 /home/useaicwl/public_html/wp-includes/class-wp-hook.php(310): LiteSpeed\Optimize->f in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php on line 126